Table 1.
Characteristic | n (%) |
---|---|
Male sex | 281 (58) |
Age at diagnosis, y | |
Median | 66 |
Range | 31-95 |
Follow-up, y | |
Median | 6.1 |
Range | 0.1-15.3 |
OS, y | |
Median | 6.4 |
95% CI | 5.9-7.2 |
PFS, y | |
Median | 2.4 |
95% CI | 2.1-2.6 |
R-ISS | |
I | 95 (20) |
II | 319 (66) |
III | 69 (14) |
FISH | |
HR by FISH | 121 (25) |
Del(17p)/monosomy 17 | 66 (14) |
Dele(13q)/monosomy 13 | 232 (48) |
Gain 1q | 101(25) |
t(4;14) | 54 (11) |
t(14;16) | 17 (4) |
t(14;20) | 1 (1) |
t(11;14) | 93 (19) |
Hyperdiploid | 63 (13) |
Metaphase cytogenetics | |
Abnormal karyotype | 108 (22) |
Del(17p)/monosomy 17 | 15 (3) |
Del(13q)/monosomy 13 | 47 (10) |
Gain 1q | 44 (9) |
Hypodiploid | 16 (3) |
Near diploid | 32 (7) |
Hyperdiploid | 58 (12) |
Nonhyperdiploid | 50 (10) |
Near triploid | 2 (1) |
Near tetraploid | 5 (1) |
PCPro ≥2% | 92 (19) |
First-line treatment | |
IMiD monotherapy | 313 (65) |
PI monotherapy | 119 (25) |
Combined IMiD/PI | 51 (10) |
ASCT | 137 (28) |
Percentages reflect the entire cohort of 483 patients, with the exception of FISH gain 1q, for which only 405 patients had data available.
ASCT, autologous hematopoietic stem cell transplantation.